Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03CDH
|
|||
Former ID |
DNC010007
|
|||
Drug Name |
3-Benzyl-4-hydroxy-2H-benzo[h]chromen-2-one
|
|||
Synonyms |
CHEMBL576081
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
![]() |
Download2D MOL |
||
Formula |
C20H18O3
|
|||
Canonical SMILES |
C1CCC2=C(C1)C=CC3=C2OC(=O)C(=C3O)CC4=CC=CC=C4
|
|||
InChI |
1S/C20H18O3/c21-18-16-11-10-14-8-4-5-9-15(14)19(16)23-20(22)17(18)12-13-6-2-1-3-7-13/h1-3,6-7,10-11,21H,4-5,8-9,12H2
|
|||
InChIKey |
AGXYLUCTDKGDGR-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Quinone reductase 1 (NQO1) | Target Info | Inhibitor | [1] |
KEGG Pathway | Ubiquinone and other terpenoid-quinone biosynthesis | |||
NetPath Pathway | TCR Signaling Pathway | |||
Pathwhiz Pathway | Vitamin K Metabolism | |||
Pathway Interaction Database | Validated transcriptional targets of TAp63 isoforms | |||
WikiPathways | Estrogen metabolism | |||
Oxidative Stress | ||||
Transcriptional activation by NRF2 | ||||
NRF2 pathway | ||||
Nuclear Receptors Meta-Pathway | ||||
Aryl Hydrocarbon Receptor Pathway | ||||
Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
Metabolism of amino acids and derivatives | ||||
Aryl Hydrocarbon Receptor | ||||
Dopamine metabolism | ||||
Arylhydrocarbon receptor (AhR) signaling pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26;52(22):7142-56. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.